iwCLL 2025 | The incidence and management of autoimmune cytopenias in patients with CLL receiving acalabrutinib

We have here at iwCLL, we have a poster showing the outcome of patients having both pre-existing autoimmune cytopenia at the time of acalabrutinib treatment initiation and of patients who are experiencing a new onset of autoimmune cytopenia during acalabrutinib treatment. 

Basically, what we see is that acalabrutinib has a positive, a beneficial effect on the outcome and the management of autoimmune cytopenia. And the treatment-emergent autoimmune cytopenia, so the new episodes of autoimmune cytopenia occurring in patients without a previous history of autoimmune cytopenia, was very, very low. In the study, we have collected data from almost 300 patients treated with acalabrutinib, both in a relapsed/refractory and treatment-naive setting. And only five of these patients actually experienced a new-onset autoimmune cytopenia episode. And actually, also the newly occurring episodes usually had a good outcome, not needing treatment interruption and allowing to achieve a good control of the autoimmune phenomena with the standard treatment. In addition, I would say that the presence of an autoimmune phenomenon did not impact the effectiveness of the acalabrutinib treatment in terms of both progression-free survival and overall survival.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.